Creative Medical Technology Holdings CELZ
NASDAQ CELZ
$0.63 +0.03 (+5.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Creative Medical Technology Holdings (CELZ) Net Income Attributable to Noncontrolling Interests (2026)

Updated

Creative Medical Technology Holdings' Net Income Attributable to Noncontrolling Interests was $726.00 in Q2 2026, down 46.6% from the prior quarter.

Analysis

Creative Medical Technology Holdings (CELZ) Net Income Attributable to Noncontrolling Interests (2026) Analysis & Trends

On a trailing twelve-month basis, Creative Medical Technology Holdings' Net Income Attributable to Noncontrolling Interests was $2,086 through Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Creative Medical Technology Holdings 50.38 Mn 21.92 Mn - 6,598.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 6,598.00
Jun 30, 2026 726.00
Mar 31, 2026 1,360.00
API Access

Creative Medical Technology Holdings Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=CELZ&period=max&api_key=YOUR_API_KEY